Phys Med Rehabil Clin N Am. 2018 Aug;29(3):473-481. doi: 10.1016/j.pmr.2018.03.003. Epub 2018 May 8.
Abstract
Multiple sclerosis is a progressive autoimmune neurologic disorder that may affect any region of the central nervous system. Spasticity in patients with multiple sclerosis can be debilitating and detrimental to the function and quality of life of patients. Treatment options include oral medications, chemodenervation, physical therapy, and modalities. Cannabinoids in the form of a delta-9-tetrahydrocannabinol/cannabidiol oro-mucosal spray has been shown to be effective in addressing spasticity in multiple sclerosis. Successful treatment of spasticity will be integrated, multimodal, and individualized.
Copyright © 2018 Elsevier Inc. All rights reserved.
KEYWORDS:
Botulinum toxin; Cannabinoids; Multiple sclerosis; Spasticity
- PMID: 30626509
- DOI: 10.1016/j.pmr.2018.03.003
-
Publication type
Publication type